Cornea - ARVO

More documents

Recommendations

Info

ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - CorneaComparison of Three Commercially Available Tear SubstitutesDesigned for Evaporative Dry Eye TreatmentCharles G. Connor, Raelyn A. Ottenbreit, Laura K. Schroeder, JeffC. Rabin, Srihari Narayanan. Rosenberg School of Optometry,University of the Incarnate Word, San Antonio, TX.Purpose: Topical rewetting agents still constitute the basis of dry eyetherapy. A high prevalence of evaporative dry eyes has generated theneed for a lipid component in rewetting agents. Our study comparesthe short term effect of 3 commercially available rewetting agentsdesigned for evaporative dry eye patients based on Non-invasive tearbreakup time (NITBUT) and contrast sensitivity.Methods: Twenty four subjects (14 female, 10 male, ave. age25.33+/-2.8 yrs) were divided into two groups based on the Effronscale for Meibomian gland dysfunction (MGD). A score of 1+ orgreater was used for inclusion in the MGD group (14 subjects). Basedon OSDI score the MGD subjects were in the mild symptomrange.The other 10 subjects served as control. Baseline measures ofVA, contrast sensitivity, OSDI and NITBUT were performed on allsubjects. Then, one drop of each of the 3 agents tested was instilled.The agents tested were Allergan Optive, Alcon Systane Balance andOcusoft Retaine. NITBUT was determined at 1.5,10,30,45 and 60minutes after instillation. Contrast was remeasured right afterinstillation. The 3 agents were tested on all subjects in 3 separatevisits.Results: A 2-way repeated measures ANOVA failed to revealsignificant differences in V.A or C.S between the two groups. Butthere was a slight improvement (25%) in contrast after dropinstillation for all agents tested.Mean NITBUT for the MGD group atbaseline with Allergan Optive was 8.4, 13.5 , 9.3 , 9.1 , 8.4 and 7.7sec (at the time points mentioned above in order) while the controlNITBUT were 9.1,10.5,9.2,9.1,8.5 and 7.7sec. The results for AlconSystane Balance were:7.7,10.7,10.6, 9.2, 8.7 and 8.4 for the MGDgroup while the control NITBUT were: 9.4,10.4,9.2,9.0,11.1 and 7.9.The results for Ocusoft Retaine were: 7.6, 9.9, 8.6, 9.5, 8.0 and 8.4for the MGD group while the control NITBUT were: 6.1,7.8, 6.2, 7.4,8.6 and 5.4 sec. Subjects preferred Optive (83%) in terms of dropcomfort, followed by Balance (62.5%) and Retaine (58%). Thelargest initial effect on the NITBUT was 5.1 seconds improvementwith Optive 90 seconds after instillation.Conclusions: Our data suggests that all 3 agents had effects thatpersisted for at least 45 minutes before a return to baseline NITBUT.Overall the NITBUT data suggests that any of these products wouldbe a reasonable choice for mild evaporative dry eye comfort in the 1hour range.Commercial Relationships: Charles G. Connor, None; Raelyn A.Ottenbreit, None; Laura K. Schroeder, None; Jeff C. Rabin,None; Srihari Narayanan, NoneProgram Number: 4323 Poster Board Number: C0061Presentation Time: 8:30 AM - 10:15 AMPlasmacytoid Dendritic Cells are the Primary Source of IFN-αDuring the Immunopathogenesis of Desiccating Stress-InducedDry Eye DiseaseMichael E. Stern 1 , Chris S. Schaumburg 1 , Jianping Gao 1 , Annie M.Ratanapinta 1 , Virginia L. Calder 2 , Larry A. Wheeler 1 , Jerry Y.Niederkorn 3 , Stephen C. Pflugfelder 4 , Bruce Beutler 5 , Argyrios N.Theofilopoulos 6 . 1 Biological Sciences, Allergan, Inc, Irvine, CA;2 Ophthalmology, University College London, London, UnitedKingdom; 3 Ophthalmology, University of Texas SouthwesternMedical School, Dallas, TX; 4 Ophthalmology, Baylor UniversityCollege of Medicine, Houston, TX; 5 Center for the Genetics of HostDefense, University of Texas Southwestern Medical School, Dallas,TX; 6 Immunology & Microbial Science, Scripps Research Institute,La Jolla, CA.Purpose: Plasmacytoid dendritic cells (pDC) and derivative type Iinterferons (IFN-α/β) are important mediators of antiviral immunityand have also been implicated in autoimmunity. The contribution ofTLR7/9 signaling in pDCs was evaluated during theimmunopathogenesis of experimental Dry Eye.Methods: Female C57BL/6 wild type mice, feeble (Slc15a4 mutants)and IFNAR1-/- mice were exposed to desiccating environmentalstress (DS; subcutaneous scopolamine injections; humidity
ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group - Corneaaveraged. Significant differences in expression levels (p
Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
Page 4 and 5:
Page 6 and 7:
Page 8 and 9:
Page 10:
Page 13 and 14:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217: ARVO 2013 Annual Meeting Abstracts
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
show all

Cornea - ARVO

Create successful ePaper yourself

Delete template?

Save as template?